The Liver Meeting 2021-Expanding HBV Treatment Criteria, New Biomarkers and Cure Updates

Expanding HBV Treatment Criteria, New Biomarkers and Cure Updates

Video Transcription

Video Summary

The video transcript covers topics such as treatment criteria and new biomarkers for Hepatitis B, focusing on differentiating phases of chronic infections using quantitative markers like surface antigen, RNA, and anti-HBC. It discusses how these markers predict outcomes, treatment responses, and disease progression, especially under nucleoside analog treatment. The importance of markers in assessing natural history, treatment response, and long-term outcomes like cirrhosis is emphasized, alongside the cost-effectiveness of screening and early intervention in high-risk populations. Dr. Nguyen highlights new markers for treatment response assessment, like siRNA and capsid assembly modulators, showing efficacy in reducing HPV DNA and predicting clinical outcomes. The discussion also touches on using quantitative core for predicting reactivation and S antigen for predicting treatment responses. The need for better biomarkers, combining antiviral drugs with immune-modifying agents, and challenges around determining endpoints and defining the target population are also mentioned.

Keywords

Hepatitis B

treatment criteria

biomarkers

chronic infections

surface antigen

RNA

anti-HBC

nucleoside analog treatment

cirrhosis

siRNA

capsid assembly modulators